Delays in Clinical Trial Start Dates as Global Trials Increase
First written in FY2017-Q1. 1 of 4 entries say "Materialised", first in FY2017-Q3. Latest entry: FY2018-Q1.
Hip moved to the "Worse" side of this theme in 2017.
0 other companies' latest entry also says "Dropped".
- FY2018-Q1DroppedAnnual report
「As a result, the Company no longer had any consolidated subsidiaries and transitioned to non-consolidated accounting from the first quarter of the fiscal year ended March 2018.」
After transferring all shares of the subsidiary that operated the SMO business, the Company no longer had any consolidated subsidiaries and became a single-segment company engaged only in the outsourcing business. Consequently, there was no longer a basis for disclosing the risk of delays in global trial starts. - FY2017WorsenedAnnual report
「In the SMO business, the number of projects won increased, mainly in dermatology, psychiatry and diabetes-related fields, and orders for peripheral SMO services also grew. However, as the number of global trials increased, pharmaceutical companies began taking longer to prepare trials, and revisions to the plans themselves also became frequent.」
The Company reported that pharmaceutical companies were taking longer to prepare for global trials and that plan revisions had become frequent, indicating that delays in trial starts had worsened and expanded. - FY2017-Q3MaterialisedAnnual report
「In the SMO business, the number of projects won increased, mainly in dermatology and psychiatry, and orders for peripheral SMO services also grew. However, as the number of global trials increased, pharmaceutical companies began taking longer to prepare trials, while revisions to the plans themselves also became frequent, resulting in delays to trial start dates.」
Trial start dates were actually delayed because pharmaceutical companies took longer to prepare and frequently revised their plans. - FY2017-Q1First statedAnnual report
「As the number of global trials increased, cases arose in which trial start dates were delayed」
Delays in trial starts due to the increase in global trials actually occurred and were cited as a factor behind the decline in performance through lower staff utilisation in the SMO business and other effects.